Loading company…
Sermonix develops lasofoxifene, an oral selective estrogen receptor modulator for ESR1-mutated breast cancer.
Founded in 2014 and based in Columbus, US, Sermonix Pharmaceuticals Inc. develops and commercializes female-specific oncology products, focused on lasofoxifene for ER-positive, HER2-negative breast cancer with an ESR1 mutation. It works with hospitals, oncology clinics and research institutions in North America and Europe. CEO David Portman leads the company. It has raised USD 40.23 mn across 3 rounds, most recently a Series A completed on November 12, 2021, led by Perceptive Advisors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in